non-compressible Biodegradable Hemostatic Agent

Award Information
Agency:
Department of Defense
Branch
Army
Amount:
$69,998.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
W81XWH-09-C-0035
Award Id:
92023
Agency Tracking Number:
A083-176-0100
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
760 Parkside Avenue, Suite 210, Brooklyn, NY, 11226
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
146587345
Principal Investigator:
MayaNowakowski
Director of Research
(718) 270-2749
majanowakowski@downstate.edu
Business Contact:
GeorgeFalus
President
(212) 719-4799
gfalus@biomedic.net
Research Institute:
n/a
Abstract
we propose to determine the biocompatibility of ClotFoam and enhance its hemostastic and non-compressible sealing effects against a severe parenchymial hemorrhage caused by a wound grade V affecting major vessels, which represents a lethal case in combat injuries. The strategy is to develop a second-generation fibrin sealant that will be carried by the current scaffold to the lacerated site. SPECIFIC AIM 1: to determine the biocompatibility, toxicity, enzymatic degradation and cell viability properties of the conjugated/modified polymers used to produce the ClotFoam scaffold. SPECIFIC AIM 2: Develop a 2nd generation of fibrin sealant that enhances platelet plug formation and provides enhanced anchors and better affinity of the fibrin clot to endothelial tissue. SPECIFIC AIM 3. Develop a standardized ex vivo model to evaluate the adhesion and sealing properties of a second generation fibrin sealant to endothelial tissue. The strategy to develop such advanced sealant includes: a) a shorter polymerization time to produce a functional fibrin clot over lacerated bleeding tissue, b) stimulation of the platelet plug formation which is the primary hemostasis process that will help stop the bleeding, c) reduction of fibrynolitic activity through the use of thrombin mutants with no affinity to protein C, d) Identification of the role of fibronectin and vitronectin as bridge molecules between cells and fibrin through binding to the a5b1-or avb3-receptor. In addition, fibronectin also binds fibrin exclusively through the aC-domain. This binding site is not accessible in fibrinogen, but becomes exposed in fibrin. Vitronectin directly associates with fibrin, preferentially to the carboxy-terminal c>-chain of the fibrin(ogen) cA/c>-chain variant.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government